{"id":46691,"date":"2026-04-09T21:01:43","date_gmt":"2026-04-09T21:01:43","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/46691\/"},"modified":"2026-04-09T21:01:43","modified_gmt":"2026-04-09T21:01:43","slug":"whats-going-on-with-c4-therapeutics-stock-thursday-c4-therapeutics-nasdaqcccc","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/46691\/","title":{"rendered":"What’s Going On With C4 Therapeutics Stock Thursday? – C4 Therapeutics (NASDAQ:CCCC)"},"content":{"rendered":"

C4 Therapeutics Inc. (NASDAQ:<\/a>CCCC<\/a>) shares rose in Thursday\u2019s session after climbing as high as $3.66 in premarket trading.<\/p>\n

The partnership focuses on developing degrader-antibody conjugates (DACs) for oncology targets, which may enhance treatment options for cancer patients<\/a>.<\/p>\n

C4 Therapeutics will receive a $20 million upfront payment for the two programs. Should Roche exercise its option for a third target, C4 Therapeutics will receive an additional payment.<\/p>\n

C4 Therapeutics Partnership Targets Cancer Drugs<\/p>\n

Across the collaboration, C4 Therapeutics will receive near-term discovery milestone payments and is eligible to receive over $1 billion in discovery, regulatory, and commercial milestone payments.<\/p>\n

In addition, C4 Therapeutics is entitled to tiered royalties on future sales.<\/p>\n

Under the joint research plan, C4 Therapeutics and Roche will collaborate on two programs to develop DACs against undisclosed oncology targets<\/a> exclusive to the collaboration.<\/p>\n

The collaboration aims to leverage C4 Therapeutics\u2019 TORPEDO platform to design degrader payloads, combining targeted protein degradation with antibody-drug conjugation.<\/p>\n

Pipeline Progress And Cash Position Support Outlook<\/p>\n

Roche will be responsible for advancing DAC candidates through preclinical and clinical development as well as commercialization.<\/p>\n

C4 Therapeutics reported<\/a> cash, cash equivalents, and marketable securities of $297.1 million as of December 31, 2025, which it expects will fund operations through the end of 2028.<\/p>\n

C4 Therapeutics in February dosed the first patient in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for RRMM.<\/p>\n

Enrollment is expected to conclude in the first quarter of 2027<\/a>.<\/p>\n

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target<\/a> of $20.72. Recent analyst moves include:<\/p>\n

Barclays: Overweight (Raises Target to $7.00) (February 27)<\/p>\n

Brookline Capital: Buy (Raises Target to $30.00) (February 23)<\/p>\n

CCCC Stock Price Activity: C4 Therapeutics shares were up 1.03% at $2.930 at the time of publication on Thursday, according to Benzinga Pro data<\/a>.<\/p>\n

Photo via Shutterstock<\/p>\n

Market News and Data brought to you by Benzinga APIs<\/a><\/p>\n

\u00a9 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.<\/p>\n

To add Benzinga News as your preferred source on Google, click here<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"C4 Therapeutics Inc. (NASDAQ:CCCC) shares rose in Thursday\u2019s session after climbing as high as $3.66 in premarket trading.…\n","protected":false},"author":2,"featured_media":46692,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[342,1016,344,346,343,345,341,340,134,27023,347,1335],"class_list":{"0":"post-46691","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-movers","12":"tag-category-news","13":"tag-category-top-stories","14":"tag-cms-wordpress","15":"tag-pageisbzpro-bz","16":"tag-roche","17":"tag-symbol-cccc","18":"tag-symbol-rhhby","19":"tag-tag-why-its-moving"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116376769906029230","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/46691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=46691"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/46691\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/46692"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=46691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=46691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=46691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}